![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
H Sands, LJ Gorey-Feret, AJ Cocuzza, FW Hobbs, D Chidester and GL Trainor
DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880.
Biodistribution and metabolism of oligonucleotides were determined using a 3H-labeled 20-nucleotide phosphodiester and its phosphorothioate analog. The oligonucleotides were radiolabeled by 3H- methylation of an internal deoxyctidine with HhaI methylase and S- [3H]adenosylmethionine. Biodistribution studies were conducted after intravenous injection of 6 mg/kg (5 muCi) oligonucleotide. Metabolism of the oligonucleotides was determined by paired-ion high performance liquid chromatography. After phosphodiester injections, radiolabel rapidly cleared the blood. Relative initial concentrations were as follows: kidney > blood > heart > liver > lung > spleen. Radiolabel in spleen peaked at 1 hr and remained elevated for 24 hr. At 2 hr the concentration in all organs, except spleen, was equal to that in blood. High performance liquid chromatographic analysis of the kidney, liver, and spleen extracts and urine indicated extremely rapid metabolism to monomer. Results of studies after the injection of phosphorothioate oligonucleotide differed from those using the phosphodiester. Despite its rapid clearance from blood, phosphorothioate accumulated rapidly in all tissues, especially the kidney. Kidney uptake increased over time, remaining very high for 24 hr. Ratios of organ to blood concentrations at 2 hr for all organs were 5:1 or greater. Kidney and liver ratios were 84:1 and 20:1, respectively. Analysis of the kidney and liver extracts and urine indicated that slow metabolism occurred. These data suggest that phosphodiester oligonucleotides would have limited therapeutic utility. The stability and organ distribution of the phosphorothioate oligonucleotide imply that such oligonucleotides may have therapeutic potential.
This article has been cited by other articles:
|
|
 |
|
  J.-H. Wang, B. M. Hendry, and C. C. Sharpe Silencing genes in the kidney: antisense or RNA interference? Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2115 - 2118. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Levesque, G. Martinez, and J. M. Fairbrother Improvement of Adjuvant Systems to Obtain a Cost-Effective Production of High Levels of Specific IgY Poult. Sci., April 1, 2007; 86(4): 630 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhou, Y. Fujigaki, A. Kato, T. Miyaji, H. Yasuda, T. Tsuji, T. Yamamoto, K. Yonemura, and A. Hishida Inhibition of p21 modifies the response of cortical proximal tubules to cisplatin in rats Am J Physiol Renal Physiol, July 1, 2006; 291(1): F225 - F235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-J. Min, S. Biswal, C. Deroose, and S. S. Gambhir Tetraphenylphosphonium as a Novel Molecular Probe for Imaging Tumors J. Nucl. Med., April 1, 2004; 45(4): 636 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Storni, C. Ruedl, K. Schwarz, R. A. Schwendener, W. A. Renner, and M. F. Bachmann Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects J. Immunol., February 1, 2004; 172(3): 1777 - 1785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma Clin. Cancer Res., August 1, 2003; 9(8): 3105 - 3114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Ho, M. S. Scully, C. M. Krauthauser, E. J. Wexler, M. D. Stow, J. E. Dinchuk, J. S. Kerr, and P. A. Friedman Antisense Oligonucleotides Selectively Regulate Aspartyl beta -Hydroxylase and Its Truncated Protein Isoform in Vitro but Distribute Poorly into A549 Tumors in Vivo J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 795 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takei, K. Kadomatsu, H. Itoh, W. Sato, K. Nakazawa, S. Kubota, and T. Muramatsu 5'-,3'-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine. ITS DESIGN AND APPLICATION FOR CANCER THERAPY J. Biol. Chem., June 21, 2002; 277(26): 23800 - 23806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Koziolkiewicz, E. Gendaszewska, M. Maszewska, C. A. Stein, and W. J. Stec The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase Blood, August 15, 2001; 98(4): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Blazar, A. M. Krieg, and P. A. Taylor Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients Blood, August 15, 2001; 98(4): 1217 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Banks, S. A. Farr, W. Butt, V. B. Kumar, M. W. Franko, and J. E. Morley Delivery across the Blood-Brain Barrier of Antisense Directed against Amyloid beta : Reversal of Learning and Memory Deficits in Mice Overexpressing Amyloid Precursor Protein J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1113 - 1121. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. Geary, T. A. Watanabe, L. Truong, S. Freier, E. A. Lesnik, N. B. Sioufi, H. Sasmor, M. Manoharan, and A. A. Levin Pharmacokinetic Properties of 2'-O-(2-Methoxyethyl)-Modified Oligonucleotide Analogs in Rats J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 890 - 897. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Wang, Q. Cai, X. Zeng, D. Yu, S. Agrawal, and R. Zhang Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration PNAS, November 23, 1999; 96(24): 13989 - 13994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nemunaitis, J. T. Holmlund, M. Kraynak, D. Richards, J. Bruce, N. Ognoskie, T. J. Kwoh, R. Geary, A. Dorr, D. Von Hoff, et al. Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3586 - 3595. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. K. Monteith, M. J. Horner, N. A. Gillett, M. Butler, R. Geary, T. Burckin, T. Ushiro-Watanabe, and A. A. Levin Evaluation of the Renal Effects of an Antisense Phosphorothioate Oligodeoxynucleotide in Monkeys Toxicol Pathol, May 1, 1999; 27(3): 307 - 317. [Abstract] [PDF]
|
|
|
|
|
|
T. Jakob, P. S. Walker, A. M. Krieg, M. C. Udey, and J. C. Vogel Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation of Th1 Responses by Immunostimulatory DNA J. Immunol., September 15, 1998; 161(6): 3042 - 3049. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gewirtz, D. L. Sokol, and M. Z. Ratajczak Nucleic Acid Therapeutics: State of the Art and Future Prospects Blood, August 1, 1998; 92(3): 712 - 736. [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Leeds, S. P. Henry, S. Bistner, S. Scherrill, K. Williams, and A. A. Levin Pharmacokinetics of an Antisense Oligonucleotide Injected Intravitreally in Monkeys Drug Metab. Dispos., July 1, 1998; 26(7): 670 - 675. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Graham, S. T. Crooke, D. K. Monteith, S. R. Cooper, K. M. Lemonidis, K. K. Stecker, M. J. Martin, and R. M. Crooke In Vivo Distribution and Metabolism of a Phosphorothioate Oligonucleotide within Rat Liver after Intravenous Administration J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 447 - 458. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. A. L. Biessen, H. Vietsch, J. Kuiper, M. K. Bijsterbosch, and T. J. C. v. Berkel Liver Uptake of Phosphodiester Oligodeoxynucleotides Is Mediated by Scavenger Receptors Mol. Pharmacol., February 1, 1998; 53(2): 262 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
K. P. Williams, X.-H. Liu, T. N. M. Schumacher, H. Y. Lin, D. A. Ausiello, P. S. Kim, and D. P. Bartel Bioactive and nuclease-resistant L-DNA ligand of vasopressin PNAS, October 14, 1997; 94(21): 11285 - 11290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Leeds, S. P. Henry, L. Truong, A. Zutshi, A. A. Levin, and D. Kornbrust Pharmacokinetics of a Potential Human Cytomegalovirus Therapeutic, a Phosphorothioate Oligonucleotide, After Intravitreal Injection in the Rabbit Drug Metab. Dispos., August 1, 1997; 25(8): 921 - 926. [Abstract] [Full Text]
|
|
|
|
|
|
M. Qian, S.-H. Chen, E. Von Hofe, and J. M. Gallo Pharmacokinetics and Tissue Distribution of a DNA-Methyltransferase Antisense (MT-AS) Oligonucleotide and Its Catabolites in Tumor-Bearing Nude Mice J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 663 - 670. [Abstract] [Full Text]
|
|
|
|
|
|
F. I. Raynaud, R. M. Orr, P. M. Goddard, H. A. Lacey, H. Lancashire, I. R. Judson, T. Beck, B. Bryan, and F. E. Cotter Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 420 - 427. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
